Statistics

Total Visits

Views
GEINO-11: A prospective multicenter, open label, phase II pilot clinical trial to evaluate safety and efficacy of Dacomitinib, a pan-HER irreversible inhibitor, in patients with recurrent glioblastoma with EGFR amplification or presence of EGFRvIII mutati10

Select a period of time:

Number of views in the range

Views
GEINO-11: A prospective multicenter, open label, phase II pilot clinical trial to evaluate safety and efficacy of Dacomitinib, a pan-HER irreversible inhibitor, in patients with recurrent glioblastoma with EGFR amplification or presence of EGFRvIII mutati6

Views

Views
November 20232
December 20230
January 20241
February 20240
March 20240
April 20240
May 20243
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States6
 

Top cities views

Views
Chicago2
Ashburn1
Boardman1
Fort Worth1